

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 26D0446044	(X3) Date Survey Completed 03/28/2023
Name of Provider or Supplier Jefferson City Medical Group	Street Address, City, State 1241 W Stadium Blvd, Jefferson City, MO	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on review of 2021, 2022 and 2023 chemistry proficiency testing (PT) results reported to the CLIA database by the PT provider and phone interview with the technical consultant, the laboratory failed to successfully participate in PT. See D-tag 2096; unsatisfactory performance in consecutive two out of three total bilirubin PT challenges.
D2096	ROUTINE CHEMISTRY CFR(s): 493.841(f)

Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on review of chemistry proficiency testing (PT) results for 2021, 2022 and 2023 and phone interview with the technical consultant, the laboratory failed to achieve satisfactory performance for the total bilirubin analyte in consecutive two out of three PT events. Findings: 1. Review of chemistry PT results for the third event of 2021 revealed the laboratory obtained an unacceptable score of 20 percent for the total bilirubin analyte. 2. Review of chemistry PT results for the second event of 2022 revealed the laboratory obtained an unacceptable score of 40 percent for the total bilirubin analyte. 3. Review of chemistry PT results for the first event of 2023 revealed the laboratory obtained an unacceptable score of 40 percent for the total bilirubin analyte. 4. Phone interview with the technical consultant on March 28, 2023 @ 08:39 AM confirmed the laboratory failed to achieve satisfactory performance for total bilirubin in consecutive two out of three testing events.